A secondary analysis of the Women's Health Initiative (WHI) randomized clinical trials reported that BMI is associated with a dose-response increased postmenopausal breast cancer risk, particularly for ER and PR positive disease [10]. The gene discussed is ESR1; the disease is breast carcinoma.